“Hairy Cell Leukemia (HCL): ‘Real World’ Outcome”
Tóm tắt
HCL is an uncommon B cell lympho-proliferative disorder with high remission rates. There is paucity of data on the long-term outcome of HCL from India. We retrospectively collected data from individual case records of patients with HCL who were treated in Cancer Institute, Chennai from January 2001 until January 2018. Sixteen patients were diagnosed with HCL and were treated with cladribine (81%), interferon (13%) and one patient received only best supportive care (6%). All the treated patients achieved complete response. More than half of the patients developed febrile neutropenia but there were no treatment related mortality. The 5-year DFS was 77% and 5-year OS was 80%. Relapse of disease was seen in 27%. HCL is a curable malignancy with high remission rates and survival comparable to patient treated in west.
Tài liệu tham khảo
Jain P, Pemmaraju N, Ravandi F (2014) Update on the biology and treatment options for hairy cell leukemia. Curr Treat Options Oncol 15:187–209
Polliack A (2002) Hairy cell leukemia: biology, clinical diagnosis, unusual manifestations and associated disorders. Rev Clin Exp Hematol 6(4):366–388
Bouroncle BA (1979) Leukemic reticuloendotheliosis (hairy cell leukemia). Blood 53:412–436
Else M, Dearden CE, Matutes E, Garcia-Talavera J, Rohatiner AZS et al (2009) Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol
Grever MR, Abdel-Wahab O, Andritsos LA et al (2017) Consensus guidelines for the diagnosis and management of patients with classical hairy cell leukemia. Blood 129:553–560
Somasundaram V, Purohit A, Aggarwal M, Manivannan P, Mishra P, Seth T et al (2014) Hairy cell leukemia: a decade long experience of North Indian Hematology Center. Indian J Med Paediatr Oncol 35:271–275
Abraham LJ, Saldanha SC, Kuntegowdanahalli LC, Bharatnur S, Dasappa L, Babu G, Babu MS, Kiran PR (2016) Hairy cell leukemia—clinical profile and treatment outcome from a Tertiary Regional Cancer Institute in South India. Clin Cancer Investig J 5:141–145
Naing PT, Acharya U (2018) Cancer, leukemia, hairy cell. In: StatPearls. StatPearls Publishing, Treasure Island (FL). http://www.ncbi.nlm.nih.gov/books/NBK499845/. Accessed 9 Sept 2018
Favre R, Manzoni D, Traverse-Glehen A, Verney A, Jallades L, Callet-Bauchu E, Sujobert P, Salles G, Baseggio L (2018) Usefulness of CD200 in the differential diagnosis of SDRPL, SMZL, and HCL. Int J Lab Hematol 40(4):e59–e62. https://doi.org/10.1111/ijlh.12824
Sigal DS, Sharpe R, Burian C, Saven A (2010) Very long-term eradication of minimal residual disease in patients with hairy cell leukemia after a single course of cladribine. Blood 115(10):1893–1896. https://doi.org/10.1182/blood-2009-10-251645
Kreitman RJ et al (2018) Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up. https://www.ncbi.nlm.nih.gov/pubmed/29487070. Accessed 19 Nov 2018
Lad DP, Malhotra P, Khadwal A et al (2014) Outcomes of splenectomy versus cladribine for hairy cell leukemia in resource limited settings. Leukemia Lymphoma 55(6):1428–1430. https://doi.org/10.3109/10428194.2013.839786
Golomb HM (2008) Hairy cell leukemia: treatment successes in the past 25 years. J Clin Oncol 26(16):2607–2609
Dinmohamed AG, Posthuma EFM, Visser O, Kater AP, Raymakers RAP, Doorduijn JK (2018) Relative survival reaches a plateau in hairy cell leukemia: a population-based analysis in The Netherlands. Blood 131(12):1380–1383. https://doi.org/10.1182/blood-2017-12-820381
Andrasiak I, Rybka J, Wrobel T (2018) Response to the therapy in hairy cell leukemia: systematic review and meta-analysis. Clin Lymphoma Myeloma Leukemia 18:392–399
Kreitman RJ, Dearden C, Zinzani PL, Delgado J, Karlin L, Robak T, Gladstone DE et al (2018) Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. Leukemia 32(8):1768–1777. https://doi.org/10.1038/s41375-018-0210-1
Andritsos LA, Grieselhuber NR, Anghelina M, Rogers KA, Roychowdhury S, Reeser JW, Timmers CD et al (2018) Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia. Leukemia Lymphoma 59(4):1008–1011. https://doi.org/10.1080/10428194.2017.1365853
Kreitman RJ, Arons E (2018) Update on hairy cell leukemia. Clin Adv Hematol Oncol H&O 16(3):205–215
Maitre E, Bertrand P, Maingonnat C, Viailly P-J, Wiber M, Naguib D, Salaün V et al (2018) New generation sequencing of targeted genes in the classical and the variant form of hairy cell leukemia highlights mutations in epigenetic regulation genes. Oncotarget 9(48):28866–28876. https://doi.org/10.18632/oncotarget.25601
Sigal DS, Sharpe R, Burian C, Saven A (2010) Very long-term eradication of minimal residual disease in patients with hairy cell leukemia after a single course of cladribine. Blood 115(10):1893–1896. https://doi.org/10.1182/blood-2009-10-251645
Galani KS, Subramanian PG, Gadage VS, Rahman K, Ashok Kumar MS, Shinde S et al (2012) Clinico-pathological profile of Hairy cell leukemia: critical insights gained at a tertiary care cancer hospital. Indian J Pathol Microbiol 55:61–65
Medhi K et al (2006) Hairy cell leukemia: experience at a tertiary cancer centre in Northern India. Indian J Med Paediatric Oncol 27(1):8–14
Gupta AK, Sachdeva MUS, Ahluwalia J et al (2015) Haematological profile of 21 patients with hairy cell leukaemia in a tertiary care centre of north India. Indian J Med Res 142(4):426–429
Chatterjee T, Panigrahi I, Mahapatra M, Pati HP, Kumar R, Naithani R et al (2008) Hairy cell leukemia: clinical, pathological and ultrastructural findings in Asian-Indians. Indian J Cancer 45:41–44